FR2873699B1 - Nouveaux anticorps anti igf ir rt leurs utilisations - Google Patents

Nouveaux anticorps anti igf ir rt leurs utilisations

Info

Publication number
FR2873699B1
FR2873699B1 FR0408379A FR0408379A FR2873699B1 FR 2873699 B1 FR2873699 B1 FR 2873699B1 FR 0408379 A FR0408379 A FR 0408379A FR 0408379 A FR0408379 A FR 0408379A FR 2873699 B1 FR2873699 B1 FR 2873699B1
Authority
FR
France
Prior art keywords
novel anti
igf antibodies
igf
antibodies
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0408379A
Other languages
English (en)
Other versions
FR2873699A1 (fr
Inventor
Liliane Goetsch
Nathalie Corvaia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2873699(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0408379A priority Critical patent/FR2873699B1/fr
Priority to BRPI0513890-6A priority patent/BRPI0513890A/pt
Priority to EP20110161875 priority patent/EP2365005A3/fr
Priority to CN2005800251969A priority patent/CN101014625B/zh
Priority to EP05780625.9A priority patent/EP1771481B1/fr
Priority to NZ569718A priority patent/NZ569718A/en
Priority to JP2007523178A priority patent/JP5016487B2/ja
Priority to MX2007001109A priority patent/MX2007001109A/es
Priority to AU2005268505A priority patent/AU2005268505B2/en
Priority to EP20110161877 priority patent/EP2380912A1/fr
Priority to KR1020077004904A priority patent/KR101220635B1/ko
Priority to CA002575348A priority patent/CA2575348A1/fr
Priority to PCT/IB2005/002619 priority patent/WO2006013472A2/fr
Priority to EP11161878A priority patent/EP2365006A3/fr
Priority to RU2007107589/10A priority patent/RU2406729C2/ru
Priority to NZ552821A priority patent/NZ552821A/en
Priority to CN201310216929.3A priority patent/CN103951752A/zh
Priority to US11/658,739 priority patent/US7854930B2/en
Priority to GT200500205A priority patent/GT200500205A/es
Priority to TW094125515A priority patent/TWI432451B/zh
Priority to CO05074351A priority patent/CO5700152A1/es
Priority to PA20058640601A priority patent/PA8640601A1/es
Priority to SV2005002182A priority patent/SV2006002182A/es
Priority to ARP050103179A priority patent/AR050036A1/es
Publication of FR2873699A1 publication Critical patent/FR2873699A1/fr
Priority to ZA200700593A priority patent/ZA200700593B/en
Priority to IL181025A priority patent/IL181025A/en
Priority to NO20071093A priority patent/NO20071093L/no
Priority to HK07110853.8A priority patent/HK1102600A1/xx
Application granted granted Critical
Publication of FR2873699B1 publication Critical patent/FR2873699B1/fr
Priority to RU2009138977/10A priority patent/RU2009138977A/ru
Priority to US12/973,480 priority patent/US8124079B2/en
Priority to US13/352,976 priority patent/US8420085B2/en
Priority to JP2012038645A priority patent/JP2012153692A/ja
Priority to IL229778A priority patent/IL229778A0/en
Priority to JP2014053009A priority patent/JP2014193862A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
FR0408379A 2004-07-29 2004-07-29 Nouveaux anticorps anti igf ir rt leurs utilisations Expired - Fee Related FR2873699B1 (fr)

Priority Applications (34)

Application Number Priority Date Filing Date Title
FR0408379A FR2873699B1 (fr) 2004-07-29 2004-07-29 Nouveaux anticorps anti igf ir rt leurs utilisations
AU2005268505A AU2005268505B2 (en) 2004-07-29 2005-07-27 Novel anti-IGF-IR antibodies and uses thereof
KR1020077004904A KR101220635B1 (ko) 2004-07-29 2005-07-27 신규한 항-ｉｇｆ-ｉｒ 항체 및 그의 용도
CN2005800251969A CN101014625B (zh) 2004-07-29 2005-07-27 新抗-igf-ir抗体及其用途
EP05780625.9A EP1771481B1 (fr) 2004-07-29 2005-07-27 Nouveaux anticorps anti-igf-ir et utilisations
NZ569718A NZ569718A (en) 2004-07-29 2005-07-27 Novel anti-IGF-IR antibodies and uses thereof
JP2007523178A JP5016487B2 (ja) 2004-07-29 2005-07-27 新規な抗ｉｇｆ−ｉｒ抗体及びその使用
MX2007001109A MX2007001109A (es) 2004-07-29 2005-07-27 Novedosos anticuerpos anti-igf-ir y usos de los mismos.
BRPI0513890-6A BRPI0513890A (pt) 2004-07-29 2005-07-27 anticorpo, hibridoma murino, composição, uso dos mesmos, e, método de diagnóstico in vitro de doenças
EP20110161877 EP2380912A1 (fr) 2004-07-29 2005-07-27 Nouveaux anticorps anti-IGF-IR et leurs utilisations
EP20110161875 EP2365005A3 (fr) 2004-07-29 2005-07-27 Nouveaux anticorps anti-IGF-IR et leurs utilisations
CA002575348A CA2575348A1 (fr) 2004-07-29 2005-07-27 Nouveaux anticorps anti-igf-ir et utilisations
PCT/IB2005/002619 WO2006013472A2 (fr) 2004-07-29 2005-07-27 Nouveaux anticorps anti-igf-ir et utilisations
EP11161878A EP2365006A3 (fr) 2004-07-29 2005-07-27 Nouveaux anticorps anti-IGF-IR et leurs utilisations
RU2007107589/10A RU2406729C2 (ru) 2004-07-29 2005-07-27 Новые анти-igf-ir и их применение
NZ552821A NZ552821A (en) 2004-07-29 2005-07-27 Novel anti-IGF-IR antibodies and uses thereof
CN201310216929.3A CN103951752A (zh) 2004-07-29 2005-07-27 新抗-igf-ir抗体及其用途
US11/658,739 US7854930B2 (en) 2004-07-29 2005-07-27 Anti-igf-ir antibodies and uses thereof
GT200500205A GT200500205A (es) 2004-07-29 2005-07-28 Nuevos anticuerpos anti-igf-ir y sus usos
PA20058640601A PA8640601A1 (es) 2004-07-29 2005-07-28 Nuevos anticuerpos anti-igf-ir y sus usos
TW094125515A TWI432451B (zh) 2004-07-29 2005-07-28 新穎之抗ｉｇｆ-ｉｒ抗體及其用途
CO05074351A CO5700152A1 (es) 2004-07-29 2005-07-28 Nuevos anticuerpos anti-igf-ir y sus usos
SV2005002182A SV2006002182A (es) 2004-07-29 2005-07-29 Nuevos anticuerpos anti-igf-1r y sus usos ref. 348207/d22514 mip
ARP050103179A AR050036A1 (es) 2004-07-29 2005-07-29 Anticuerpos anti - igf- ir y sus usos
ZA200700593A ZA200700593B (en) 2004-07-29 2007-01-22 Novel anti-IGF-IR antibodies and uses thereof
IL181025A IL181025A (en) 2004-07-29 2007-01-29 Antibodies against ir-igf, their use and preparations that include them
NO20071093A NO20071093L (no) 2004-07-29 2007-02-27 Nye anti-IGF-IR-antistoffer og anvendelse derav
HK07110853.8A HK1102600A1 (en) 2004-07-29 2007-10-05 Novel anti-igf-ir antibodies and uses thereof
RU2009138977/10A RU2009138977A (ru) 2004-07-29 2009-10-21 Новые анти-igf-ir антитела и их применение
US12/973,480 US8124079B2 (en) 2004-07-29 2010-12-20 Anti-IGF-IR antibodies and uses thereof
US13/352,976 US8420085B2 (en) 2004-07-29 2012-01-18 Anti-IGF-IR antibodies and uses thereof
JP2012038645A JP2012153692A (ja) 2004-07-29 2012-02-24 新規な抗ｉｇｆ−ｉｒ抗体及びその使用
IL229778A IL229778A0 (en) 2004-07-29 2013-12-03 Antibodies against ir-igf, their use and preparations that include them
JP2014053009A JP2014193862A (ja) 2004-07-29 2014-03-17 新規な抗ｉｇｆ−ｉｒ抗体及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408379A FR2873699B1 (fr) 2004-07-29 2004-07-29 Nouveaux anticorps anti igf ir rt leurs utilisations

Publications (2)

Publication Number Publication Date
FR2873699A1 FR2873699A1 (fr) 2006-02-03
FR2873699B1 true FR2873699B1 (fr) 2009-08-21

Family

ID=34950307

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408379A Expired - Fee Related FR2873699B1 (fr) 2004-07-29 2004-07-29 Nouveaux anticorps anti igf ir rt leurs utilisations

Country Status (23)

Country Link
US (3) US7854930B2 (fr)
EP (4) EP2365006A3 (fr)
JP (3) JP5016487B2 (fr)
KR (1) KR101220635B1 (fr)
CN (2) CN101014625B (fr)
AR (1) AR050036A1 (fr)
AU (1) AU2005268505B2 (fr)
BR (1) BRPI0513890A (fr)
CA (1) CA2575348A1 (fr)
CO (1) CO5700152A1 (fr)
FR (1) FR2873699B1 (fr)
GT (1) GT200500205A (fr)
HK (1) HK1102600A1 (fr)
IL (2) IL181025A (fr)
MX (1) MX2007001109A (fr)
NO (1) NO20071093L (fr)
NZ (2) NZ569718A (fr)
PA (1) PA8640601A1 (fr)
RU (2) RU2406729C2 (fr)
SV (1) SV2006002182A (fr)
TW (1) TWI432451B (fr)
WO (1) WO2006013472A2 (fr)
ZA (1) ZA200700593B (fr)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2365001A3 (fr) 2003-05-01 2012-03-28 Imclone LLC Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EP2283831A3 (fr) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarqueurs pour la présélection des patients pour la thérapie anti-IGF1R
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
DK2100618T3 (en) 2005-06-17 2014-03-03 Imclone Llc Anti-PDGFR alpha antibody for use in the treatment of metastatic bone cancer
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2007092453A2 (fr) 2006-02-03 2007-08-16 Imclone Systems Incorporated Antagonistes d'igf-ir en tant qu'adjuvants au traitement du cancer de la prostate
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
MX2009008754A (es) * 2007-02-14 2009-11-02 Glaxo Group Ltd Anticuerpos novedosos contra igf-1r.
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CA2778105C (fr) 2009-10-23 2019-04-02 Amgen Inc. Adaptateur de fiole et systeme
BR112012009828B8 (pt) 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
US8444982B2 (en) * 2009-12-04 2013-05-21 The University Of Hong Kong Anti-IGF-IR antibodies and uses thereof
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
AU2011265005B2 (en) 2010-06-07 2015-04-09 Amgen Inc. Drug delivery device
WO2011161119A1 (fr) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Anticorps contre le récepteur du facteur de croissance insulinique i et ses utilisations
EP3604339B1 (fr) 2011-01-14 2021-03-10 The Regents Of The University Of California Anticorps thérapeutiques contre la protéine ror-1 et leurs procédés d'utilisation
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
HUE042822T2 (hu) 2011-04-20 2019-07-29 Amgen Inc Automata befecskendezõ szerkezet
WO2013055873A1 (fr) 2011-10-14 2013-04-18 Amgen Inc. Injecteur et procédé d'assemblage
EP2776042B1 (fr) 2011-11-11 2019-03-20 Duke University Polythérapie médicamenteuse pour le traitement de tumeurs solides
EP2631653A1 (fr) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification de modulateurs de liaison des propriétés d'anticorps réactifs avec un élément de la famille des récepteurs de l'insuline
JP6388576B2 (ja) * 2012-06-21 2018-09-12 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｉｇｆ１ｒに結合する抗原結合タンパク質
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN102830223A (zh) * 2012-08-14 2012-12-19 四川汇宇制药有限公司 一种筛选治疗哺乳动物肿瘤疾病药物的方法
WO2014067642A1 (fr) 2012-11-05 2014-05-08 Mab Discovery Gmbh Procédé de fabrication d'anticorps plurispécifiques
EP2727941A1 (fr) 2012-11-05 2014-05-07 MAB Discovery GmbH Procédé pour la production d'anticorps multispécifiques
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014144096A1 (fr) 2013-03-15 2014-09-18 Amgen Inc. Cartouche à médicament, auto-injecteur et système d'auto-injection
CN105377327B (zh) 2013-03-22 2021-06-22 安姆根有限公司 注射器及装配方法
CA2923160A1 (fr) 2013-09-09 2015-03-12 Canimguide Therapeutics Ab Modulateurs du systeme immunitaire
CA3168888A1 (fr) 2013-10-24 2015-04-30 Amgen Inc. Systeme de distribution de medicaments equipe d'un dispositif de commande sensible a la temperature
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
WO2015119906A1 (fr) 2014-02-05 2015-08-13 Amgen Inc. Système d'administration de médicament doté d'un générateur de champ électromagnétique
EP3783033A1 (fr) * 2014-04-25 2021-02-24 Pierre Fabre Medicament Anticorps igf-1r et son utilisation en tant que véhicule d'adressage pour le traitement du cancer
CN106413779B (zh) 2014-05-07 2020-06-05 安姆根有限公司 具有减震元件的自助注射器
WO2015187793A1 (fr) 2014-06-03 2015-12-10 Amgen Inc. Système d'administration de médicament et son procédé d'utilisation
US10695506B2 (en) 2014-10-14 2020-06-30 Amgen Inc. Drug injection device with visual and audio indicators
ES2898469T3 (es) 2014-12-19 2022-03-07 Amgen Inc Dispositivo de administración de medicamentos con sensor de proximidad
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
MX2017010466A (es) 2015-02-17 2018-06-06 Amgen Inc Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas.
WO2016138434A1 (fr) 2015-02-27 2016-09-01 Amgen Inc. Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
CA2978617A1 (fr) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Modulateurs et compositions du systeme immunitaire
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
EP3386573B1 (fr) 2015-12-09 2019-10-02 Amgen Inc. Auto-injecteur avec capuchon de signalisation
WO2017120178A1 (fr) 2016-01-06 2017-07-13 Amgen Inc. Auto-injecteur pourvu d'une électronique de signalisation
BR112018015485A2 (pt) 2016-02-06 2018-12-18 Epimab Biotherapeutics Inc imunoglobulina fabs-in-tandem e usos da mesma
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (fr) 2016-05-02 2017-11-09 Amgen Inc. Adaptateur de seringue et guide pour remplir un injecteur sur le corps
CA3018426A1 (fr) 2016-05-13 2017-11-16 Amgen Inc. Ensemble manchon de flacon
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (fr) 2016-07-01 2018-01-04 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (fr) 2016-10-25 2018-05-03 Amgen Inc. Injecteur porté sur le corps
WO2018136398A1 (fr) 2017-01-17 2018-07-26 Amgen Inc. Dispositifs d'injection et procédés d'utilisation et d'assemblage associés
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
EP3582825A1 (fr) 2017-02-17 2019-12-25 Amgen Inc. Dispositif d'administration de médicament à trajet d'écoulement de fluide stérile et procédé d'assemblage associé
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
CA3052482A1 (fr) 2017-03-07 2018-09-13 Amgen Inc. Insertion d'aiguille par surpression
KR20240005194A (ko) 2017-03-09 2024-01-11 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
JP7118993B2 (ja) 2017-03-28 2022-08-16 アムジエン・インコーポレーテツド プランジャーロッド・シリンジアセンブリシステム及び方法
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
WO2018226515A1 (fr) 2017-06-08 2018-12-13 Amgen Inc. Ensemble de seringue d'un appareil d'administration de médicament et procédé d'assemblage
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
WO2019018169A1 (fr) 2017-07-21 2019-01-24 Amgen Inc. Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (fr) 2017-10-04 2023-02-08 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
EP3691716B1 (fr) 2017-10-06 2023-11-29 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
EP3694578A1 (fr) 2017-10-09 2020-08-19 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (fr) 2017-11-03 2019-05-09 Amgen Inc. Systèmes et approches pour stériliser un dispositif d'administration de médicament
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019094138A1 (fr) 2017-11-10 2019-05-16 Amgen Inc. Pistons pour dispositifs d'administration de médicament
CA3084486A1 (fr) 2017-11-16 2019-05-23 Amgen Inc. Auto-injecteur avec detection de decrochage et de point d'extremite
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
CN112351804A (zh) 2018-07-24 2021-02-09 安进公司 用于施用药物的输送装置
MX2021000748A (es) 2018-07-24 2021-03-26 Amgen Inc Dispositivos de suministro para administrar farmacos.
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
EP3829692A1 (fr) 2018-07-31 2021-06-09 Amgen Inc. Ensemble de trajet de fluide pour dispositif d'administration de médicament
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
IL281469B1 (en) 2018-09-28 2024-04-01 Amgen Inc Assembling a memory alloy ejector activation assembly for a drug delivery device
CA3110529A1 (fr) 2018-10-02 2020-04-09 Amgen Inc. Systemes d'injection pour administration de medicament avec transmission de force interne
WO2020072846A1 (fr) 2018-10-05 2020-04-09 Amgen Inc. Dispositif d'administration de médicament ayant un indicateur de dose
AU2019361919A1 (en) 2018-10-15 2021-03-18 Amgen Inc. Drug delivery device having damping mechanism
TW202031306A (zh) 2018-10-15 2020-09-01 美商安進公司 用於藥物遞送裝置之平台組裝方法
EP3873567A1 (fr) 2018-11-01 2021-09-08 Amgen Inc. Dispositifs d'administration de médicament à rétraction d'aiguille partielle
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
JP2022529319A (ja) 2019-04-24 2022-06-21 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
CA3148261A1 (fr) 2019-08-23 2021-03-04 Amgen Inc. Dispositif d'administration de medicament dote de composants configurables de mise en prise de protection d'aiguille et methodes associees
WO2022086620A1 (fr) * 2020-10-20 2022-04-28 The Methodist Hospital System Immunothérapies ciblées par psma pour des cancers
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
AU4171001A (en) * 2000-02-25 2001-09-03 Univ California Membrane estrogen receptor-directed therapy in breast cancer
CA2433800C (fr) * 2001-01-05 2016-09-13 Pfizer Inc. Anticorps anti-recepteur du facteur de croissance insulinoide i
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
EP1798242B1 (fr) * 2002-01-18 2013-01-23 Pierre Fabre Medicament Anticorps anti-IGF-IR et leurs applications
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
PL210412B1 (pl) * 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
CA2519113C (fr) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
PT1656391E (pt) * 2003-08-13 2010-12-06 Pfizer Prod Inc Anticorpos humanos modificados contra igf-ir
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Also Published As

Publication number Publication date
JP2014193862A (ja) 2014-10-09
US20120183559A1 (en) 2012-07-19
TWI432451B (zh) 2014-04-01
AU2005268505A1 (en) 2006-02-09
PA8640601A1 (es) 2006-08-03
EP2365006A2 (fr) 2011-09-14
US20090214525A1 (en) 2009-08-27
US20110091479A1 (en) 2011-04-21
CN103951752A (zh) 2014-07-30
CN101014625A (zh) 2007-08-08
RU2009138977A (ru) 2011-04-27
AU2005268505B2 (en) 2011-11-17
JP2008515773A (ja) 2008-05-15
NZ552821A (en) 2009-10-30
IL181025A0 (en) 2007-07-04
GT200500205A (es) 2006-03-02
US7854930B2 (en) 2010-12-21
SV2006002182A (es) 2006-10-04
JP5016487B2 (ja) 2012-09-05
JP2012153692A (ja) 2012-08-16
RU2007107589A (ru) 2008-09-10
EP2380912A1 (fr) 2011-10-26
ZA200700593B (en) 2008-05-28
EP2365005A2 (fr) 2011-09-14
CO5700152A1 (es) 2006-11-30
MX2007001109A (es) 2007-04-19
CA2575348A1 (fr) 2006-02-09
KR101220635B1 (ko) 2013-01-11
CN101014625B (zh) 2013-07-03
AR050036A1 (es) 2006-09-20
WO2006013472A2 (fr) 2006-02-09
EP2365005A3 (fr) 2011-10-26
IL181025A (en) 2013-12-31
EP2365006A3 (fr) 2011-10-19
EP1771481B1 (fr) 2014-05-14
BRPI0513890A (pt) 2008-05-20
FR2873699A1 (fr) 2006-02-03
TW200628490A (en) 2006-08-16
US8420085B2 (en) 2013-04-16
RU2406729C2 (ru) 2010-12-20
HK1102600A1 (en) 2007-11-30
NZ569718A (en) 2010-03-26
WO2006013472A3 (fr) 2006-05-11
NO20071093L (no) 2007-02-27
KR20070057814A (ko) 2007-06-07
IL229778A0 (en) 2014-01-30
EP1771481A2 (fr) 2007-04-11
US8124079B2 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
FR2873699B1 (fr) Nouveaux anticorps anti igf ir rt leurs utilisations
CY2018027I1 (el) Ανταγωνιστικα αντισωματα il-17
CY2016030I1 (el) Αντισωματα εναντι της il-17
CY2019041I1 (el) Τροποποιημενα αντισωματα εναντι il-23
DK1794586T3 (da) Monoklonale antistoffer til progastrin
DK2177537T3 (da) Antistoffer til MAdCAM
NO20071430L (no) Anti-OX4OL antistoffer
NL1033650A1 (nl) Antilichamen tegen myostatine.
DK1737891T3 (da) Anti-p-selectin-antistoffer
ATE483732T1 (de) Madcam-antikörper
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
BRPI0809677A2 (pt) Anticorpos anti-ige
DE502005004034D1 (de) Kämmmaschine.
DE602005015436D1 (de) Brennstoffsystem
FR2922212B1 (fr) Anticorps anti ricine
NO20051710D0 (no) Sprengstoff
NO20055630L (no) SmartCoupling - non responsive
DE602005013453D1 (de) Drosselklappe
FI6637U1 (fi) Kantopeite
DE602004010481D1 (de) Knallkörper für entfernte Explosion
SE0402943D0 (sv) Vitt snus
SE0401067D0 (sv) Ett av en operatör bärbart arrangemang
NO20044471D0 (no) Tobakksetui
ITPI20040043A1 (it) Liquore coccolone

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150331